Liang-Chuan S Wang
Overview
Explore the profile of Liang-Chuan S Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koblish H, Wu L, Wang L, Liu P, Wynn R, Rios-Doria J, et al.
Cancer Discov
. 2022 Mar;
12(6):1482-1499.
PMID: 35254416
Significance: We have identified a potent small-molecule inhibitor of PD-L1, INCB086550, which has biological properties similar to PD-L1/PD-1 monoclonal antibodies and may represent an alternative to antibody therapy. Preliminary clinical...
2.
Moon E, Wang L, Bekdache K, Lynn R, Lo A, Thorne S, et al.
Oncoimmunology
. 2018 Feb;
7(3):e1395997.
PMID: 29399394
T cell trafficking into tumors depends on a "match" between chemokine receptors on effector cells (e.g., CXCR3 and CCR5) and tumor-secreted chemokines. There is often a chemokine/chemokine receptor "mismatch", with...
3.
Liu Y, OLeary C, Wang L, Bhatti T, Dai N, Kapoor V, et al.
Oncoimmunology
. 2016 Mar;
5(1):e1061175.
PMID: 26942073
Neutrophils are important innate immune cells involved in microbial clearance at the sites of infection. However, their role in cancer development is unclear. We hypothesized that neutrophils mediate antitumor effects...
4.
Xiao H, Jiao J, Wang L, OBrien S, Newick K, Wang L, et al.
Int J Cancer
. 2015 Dec;
138(10):2477-86.
PMID: 26704363
Histone/protein deacetylases (HDACs) are frequently upregulated in human malignancies and have therefore become therapeutic targets in cancer therapy. However, inhibiting certain HDAC isoforms can have protolerogenic effects on the immune...
5.
Lo A, Wang L, Scholler J, Monslow J, Avery D, Newick K, et al.
Cancer Res
. 2015 May;
75(14):2800-2810.
PMID: 25979873
Malignant cells drive the generation of a desmoplastic and immunosuppressive tumor microenvironment. Cancer-associated stromal cells (CASC) are a heterogeneous population that provides both negative and positive signals for tumor cell...
6.
Wang L, Lo A, Scholler J, Sun J, Majumdar R, Kapoor V, et al.
Cancer Immunol Res
. 2014 Apr;
2(2):154-66.
PMID: 24778279
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may...
7.
Wang L, Riese M, Moon E, Albelda S
Oncoimmunology
. 2014 Feb;
2(11):e26492.
PMID: 24490126
Effector T cells become rapidly inactivated after antigen exposure due to extracellular as well as intrinsic signals. We have recently demonstrated that the deletion of diacylglycerol kinases, intrinsic inhibitors of...
8.
Liu Y, Wang L, Predina J, Han R, Beier U, Wang L, et al.
Nat Med
. 2013 Aug;
19(9):1173-7.
PMID: 23955711
Forkhead box P3 (Foxp3)(+) T regulatory (T(reg)) cells maintain immune homeostasis and limit autoimmunity but can also curtail host immune responses to various types of tumors. Foxp3(+) T(reg) cells are...
9.
Riese M, Wang L, Moon E, Joshi R, Ranganathan A, June C, et al.
Cancer Res
. 2013 Apr;
73(12):3566-77.
PMID: 23576561
Recent clinical trials have shown promise in the use of chimeric antigen receptor (CAR)-transduced T cells; however, augmentation of their activity may broaden their clinical use and improve their efficacy....
10.
Wang L, Lynn R, Cheng G, Alexander E, Kapoor V, Moon E, et al.
Mol Ther
. 2011 Oct;
20(4):736-48.
PMID: 22008913
Since previous work using a nonreplicating adenovirus-expressing mouse interferon-β (Ad.mIFNβ) showed promising preclinical activity, we postulated that a vector-expressing IFNβ at high levels that could also replicate would be even...